Dermira's Qbrexa Cloth Now Available for Primary Axillary Hyperhidrosis

Dermira, Inc.'s Qbrexa (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis. The new therapy is available in retail and community pharmacies nationwide. In June 2018, QBREXZA, a once-daily, prescription anticholinergic, was FDA approved to treat adult and pediatric patients 9 years of age and older living with this chronic, medical skin condition.

“People living with primary axillary hyperhidrosis often report feelings of isolation, and struggle in silence for years before finally speaking to a healthcare professional. In most instances, people are often too embarrassed to seek treatment, and when they do, they may not find solutions that effectively control their excessive underarm sweating,” said Lisa J. Pieretti, Executive Director for the International Hyperhidrosis Society and a patient advocate for more than 15 years. “The availability of QBREXZA represents an FDA-approved, topical medicine for the millions of adults and children who may be looking for a new way to treat their excessive underarm sweating. It is my hope that many of these sufferers will finally get the sweat help they have been seeking much of their lives.”

To provide seamless and affordable access to Qbrexa, Dermira recently launched DermiraConnect. The program is designed to offer financial assistance and other customized support services to eligible patients and healthcare professionals seeking to access Qbrexa.

To date, Dermira has secured coverage for approximately 53 percent of the total US commercial lives, exceeding its goal of securing more than 30 percent coverage by October 1, 2018 and 50 percent coverage by January 1, 2019. In addition to Express Scripts, Inc. and OptumRx, several other payers have also agreed to provide access to Qbrexa through their national formularies beginning October 1.

“We are thrilled that Qbrexa is now available to dermatologists and patients as a new treatment option for primary axillary hyperhidrosis,” said Tom Wiggans, chairman and chief executive officer at Dermira. “This condition can have a significant impact on the way people with this condition feel and the choices they make in their lives. We hope that patients treated with Qbrexa not only experience a reduction in sweat, but also a renewed confidence. No one, adult or child, should feel isolated or suffer in silence because of a treatable medical condition like primary axillary hyperhidrosis.”